Third-quarter sales growth of 2% on a reported basis, 5% organic Third-quarter Reconstructive sales growth of 6% on a reported and organic basis Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS
OrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026,
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow RegistryROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS)
eCential Robotics platform to join Enovis' enabling technology portfolio.GRENOBLE, France and FRANKLIN, Tenn., Sept. 1, 2026 /PRNewswire/ -- eCential Robotics, a leading developer of enabling technologies and
Enhances Enovis’ enabling technology ecosystem to include robotic automation capabilities, empowering surgeons with a broader, integrated set of precision tools in the operating room. Creates a robotics center of
Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare
Second-quarter sales growth of 3% on a reported basis, 5% organicSecond-quarter Reconstructive sales grew 8% on a reported basis, 6% organicReaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS,
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to
CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals
Spinamic combines the curve-correction efficacy of rigid bracing with the comfort and mobility of dynamic braces, offering an optimal balance of therapy and patient wearabilityAvailable in 10 off-the-shelf sizes with an
First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance
New Foundation Trustees and Company Board Appointed to Oversee Knoa Pharma's Public Health Purpose; Company Board to Ensure Safe and Responsible Operations
Knoa Pharma LLC ("Knoa Pharma") today begins operations as an
Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast
